Drug intelligence / Profile preview

UP1009

Development stage: Preclinical
Lead developer: UPPthera
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

UP1009 is a small molecule targeted protein degrader (TPD) being developed by UPPthera for the treatment of oncology. It is designed to target and induce the degradation of an undisclosed cell cycle-related protein, thereby disrupting the proliferation of cancer cells. The drug utilizes the ubiquitin-proteasome system to eliminate key proteins involved in cell cycle progression. As of early 2024, the program is in the lead optimization stage of preclinical development.

Beyond the preview

Go deeper on UP1009.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UP1009.

Explore the full profile